- Title: Subtitle
- 1093TiP An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]
- Creators
- F. Aroldi - University of OxfordM.R. Middleton - University of OxfordJ.J. Sacco - Clatterbridge Cancer Centre NHS Foundation TrustM.M. Milhem - University of IowaB.D. Curti - Providence Portland Medical CenterA.M. VanderWalde - West Cancer CenterS.L. Baum - West Cancer CenterA. Samson - University of LeedsJ. Chesney - University of LouisvilleJ. Niu - The University of Texas MD Anderson Cancer CenterT.D. Rhodes - Intermountain HealthcareT.L. Bowles - Intermountain Medical CenterA. Olsson-Brown - Clatterbridge Cancer Centre NHS Foundation TrustD.E. Laux - University of Iowa Hospitals and ClinicsP.K. Bommareddy - Translational Research, Replimune Group Inc, Woburn, MA, USAL. Menezes - Clinical Research, Replimune Group Inc, Oxfordshire, MA, UKS. Samakoglu - Clinical Research, Replimune Group Inc, Woburn, MA, USAA. Pirzkall - Clinical Research, Replimune Group Inc, Woburn, MA, USAR.S. Coffin - Clinical Research, Replimune Group Inc, Woburn, MA, USAK.J. Harrington - Institute of Cancer Research
- Resource Type
- Abstract
- Publication Details
- Annals of oncology, Vol.32, pp.S903-S904
- DOI
- 10.1016/j.annonc.2021.08.1478
- ISSN
- 0923-7534
- eISSN
- 1569-8041
- Publisher
- Elsevier Ltd
- Language
- English
- Date published
- 09/2021
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363166102771
Abstract
1093TiP An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]
Annals of oncology, Vol.32, pp.S903-S904
09/2021
DOI: 10.1016/j.annonc.2021.08.1478
Details
Metrics
31 Record Views